Q32 Bio Inc. — Director's Dealing 2020

Feb 5, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Homology Medicines, Inc. (FIXX)
CIK: 0001661998
Period of Report: 2020-02-03

Reporting Person: Smith W Bradford (CFO, Treasurer & Secretary)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-02-03	Common Stock	M	12000	$0.6316	Acquired	12000	Direct
2020-02-03	Common Stock	S	12000	$16.1555	Disposed	0	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-02-03	Employee Stock Option	$0.64	M	12000	Disposed	2027-04-05	Common Stock (12000)	Direct

Footnotes

F1: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 20, 2018.

F2: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $16.0300 to $16.3400. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3: The option vested and became exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in equal monthly installments over a three year period thereafter. The vesting commencement date for this option was April 3, 2017.